title: Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T.
abstract: OBJECTIVE
  We examined the efficacy of Suplatast Tosilatedouble dagger (IPD-1151T), a new immunoregulator that suppresses helper T cell mediated allergic responses, including IgE production and eosinophilic inflammation for treating patients with interstitial cystitis.
  
  
  METHODS
  A total of 14 women (average age 43.7 years) with interstitial cystitis, which was nonulcerative in 13 and ulcerative in 1, were treated with 300 mg. IPD-1151T orally daily for 12 months. All patients received laboratory assessments, including hematology (eosinophils and CD20 positive cells) and serum chemistry (IgE, and interleukin-4 (IL-4) and 5, and immunohistochemical analyses of urine leukocytes (CD45RO positive cells as a T cell marker) before treatment. These parameters were also measured 4 and 12 months after continuous treatment. The voiding chart, and interstitial cystitis symptom and problem indexes were evaluated before and after IPD-1151T treatment.
  
  
  RESULTS
  IPD-1151T treatment for 1 year resulted in a significantly increased bladder capacity and decreased symptoms, such as urinary urgency, frequency and lower abdominal pain, in patients with nonulcerative interstitial cystitis. These effects also correlated with a reduction in blood eosinophils, CD20 positive cells and IgE, and urine CD45RO positive memory T cells. No major side effects were observed.
  
  
  CONCLUSIONS
  Our study suggests that immunological responses are involved in the development of interstitial cystitis symptoms. IPD-1151T could be a new oral agent for treatment of voiding symptoms and bladder pain in patients with interstitial cystitis.
authors.affiliation: Department of Urology, Kouga Public Hospital, Shiga, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: M
authors.initials: M
authors.lastname: Tamaki
authors.forename: O
authors.initials: O
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Yamauchi
authors.forename: N
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D018951:Antigens, CD20 / Q000032:analysis; D001190:Arylsulfonates / Q000008:administration & dosage*; D018856:Cystitis, Interstitial / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004804:Eosinophils; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D015848:Interleukin-5 / Q000097:blood; D017493:Leukocyte Common Antigens / Q000032:analysis; D007958:Leukocyte Count; D013452:Sulfonium Compounds / Q000008:administration & dosage*; D016176:T-Lymphocyte Subsets; D006377:T-Lymphocytes, Helper-Inducer
chemical_list: D000276:Adjuvants, Immunologic; D018951:Antigens, CD20; D001190:Arylsulfonates; D015848:Interleukin-5; D013452:Sulfonium Compounds; D015847:Interleukin-4; D007073:Immunoglobulin E; C073028:suplatast tosilate; D017493:Leukocyte Common Antigens